Sugi Predict

Sugi Predict / Compounds / SCHEMBL2936966

SCHEMBL2936966

SCHEMBL2936966

O=C1N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)C2(CC2)N1Cc1ccnc2c(N3CCCCC3)cccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.55
▸ MAPK1 P28482 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ HTT P42858 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MCHR1 Q99705 8/20 0.36
▸ MAPT P10636 5/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ TRPV3 Q8NET8 1/20 0.33
▸ TNNI3 P19429 1/20 0.32
▸ TNNT2 P45379 1/20 0.32
▸ TNNC1 P63316 1/20 0.32
▸ MITF O75030 1/20 0.32
▸ CYP3A4 P08684 3/20 0.31
▸ KDM4A O75164 1/20 0.31
▸ EGLN1 Q9GZT9 1/20 0.31
▸ TRPV1 Q8NER1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932132 0.91 IGF1R (0.69) IGF1RMAPK1SMN1; SMN2HTTLMNA
SCHEMBL2934278 0.87 IGF1R (0.55) IGF1RMAPK1SMN1; SMN2HTTLMNA
SCHEMBL2932616 0.87 IGF1R (0.60) IGF1RMCHR1CYP3A4
SCHEMBL2931639 0.86 IGF1R (0.39) IGF1RMCHR1MAPTKDM4ECYP3A4
SCHEMBL2940939 0.86 IGF1R (0.42) IGF1R
SCHEMBL2937709 0.86 IGF1R (0.59) IGF1RSMN1; SMN2HTTMCHR1MAPT
SCHEMBL2941400 0.86 IGF1R (0.62) IGF1RMCHR1CYP3A4KDM4AEGLN1
SCHEMBL2932420 0.86 IGF1R (0.59) IGF1RMAPK1SMN1; SMN2HTTLMNA
SCHEMBL2940608 0.85 IGF1R (0.58) IGF1RMAPK1SMN1; SMN2HTTLMNA
SCHEMBL2939031 0.84 IGF1R (0.59) IGF1RMCHR1TRPV3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885MAPK1 53/4885SMN1; SMN2 3761/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885MAPK1 42/4885SMN1; SMN2 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.